740155
Last Update Posted: 2015-03-03
Recruiting has ended
All Genders accepted | 18 Years-45 Years |
154 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
This is part of an ongoing effort to develop a satisfactory dengue vaccine:
Primary objective:
To describe the safety after each vaccination with bivalent and tetravalent formulations of dengue vaccine candidates.
To describe the immune response after each vaccination of dengue vaccine.
Subjects will be randomized to five groups to receive assigned vaccines and followed up for 12 months.
Eligibility
Relevant conditions:
Dengue Virus
Dengue Fever
Dengue Hemorrhagic Fever
Dengue Diseases
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov